FDA grants traditional approval to Novartis’ Fabhalta for IgAN
The traditional FDA approval was supported by results from the Phase III APPLAUSE-IgAN study.
Drug Development
JCVI issues recommendation on adolescent MenB vaccination in UK
Telix opens radiopharmaceutical facility in Australia for cancer treatment
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Novartis and Chai Discovery collaborate on antibody identification
Cellares and Sonoma partner to automate cell therapy manufacturing
